Federal health officials have granted full approval to a Boehringer Ingelberg medication designed for advanced lung cancer patients who have already undergone previous treatments. The approval represents only the second drug cleared through the FDA's special Commissioner's National Priority Voucher pilot program.

Federal health regulators announced Thursday they have granted full approval to a Boehringer Ingelberg medication targeting patients battling advanced lung cancer who have already undergone previous treatments.
The Food and Drug Administration’s decision represents just the second drug to receive clearance through the agency’s Commissioner’s National Priority Voucher pilot program, a special pathway designed to expedite certain treatments.
The approval provides a new treatment option for patients facing this challenging form of cancer who have exhausted other therapeutic approaches.
Toxic Algae Bloom Kills Thousands of Crayfish on South African Coast
Pentagon Issues Ultimatum to AI Company Over Military Technology Access
Burger King Tests AI Headsets That Monitor Employee Politeness
Olympic Hockey Star Denies Anti-Canadian Slur in White House TikTok Video